Drug Profile


Alternative Names: Anti-IL-13 monoclonal antibody - Novartis; Anti-Interleukin-13 monoclonal antibody - Novartis; QAX-576

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Idiopathic pulmonary fibrosis; Keloids; Oesophagitis; Rectal fistula; Seasonal allergic rhinitis

Most Recent Events

  • 30 Jul 2015 Phase II development is ongoing
  • 01 Mar 2013 Novartis completes a phase II trial in Rectal fistula (in patients with Crohn's disease) in Germany and Switzerland (NCT01355614)
  • 01 May 2012 Phase-II clinical trials in Rectal fistula (in patients with Crohn's disease) in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top